Selected Publications

Zhang XY, Birtwistle MR, Gallo JM. A general network pharmacodynamic model-based design pipeline for customized cancer therapy applied to the VEGFR pathway. CPT Pharmacometrics Syst Pharmacol. 2014 Jan 15;3:e92.

Birtwistle MR, Mager DE, Gallo JM. Mechanistic vs. empirical network models of drug action. CPT Pharmacometrics Syst Pharmacol. 2013 2, e72.

Sharma J, Lv H, Gallo JM. Intratumoral modeling of gefitinib pharmacokinetics and pharmacodynamics in an orthotopic mouse model of glioblastoma. Cancer Res. 2013 Aug 15;73(16):5242-52.

Tiwari AK, Zhang R, Gallo JM. Overlapping functions of ABC transporters in topotecan disposition as determined in gene knockout mouse models. Mol Cancer Ther. 2013 Jul;12(7):1343-55.

Gallo JM. Physiologically based pharmacokinetic models of tyrosine kinase inhibitors: a systems pharmacological approach to drug disposition. Clin Pharmacol Ther. 2013 Mar;93(3):236-8.

Lv H, Zhang X, Sharma J, Reddy MV, Reddy EP, Gallo JM. Integrated pharmacokinetic-driven approach to screen candidate anticancer drugs for brain tumor chemotherapy. AAPS J. 2013 Jan;15(1):250-7.

Zhou Q, Lv H, Mazloom AR, Xu H, Ma'ayan A, Gallo JM. Activation of Alternate Pro-Survival Pathways Accounts for Acquired Sunitinib Resistance in U87MG Glioma Xenografts. J Pharmacol Exp Ther. 2012 Nov;343(2):509-19.

Sharma J, Lv H, Gallo JM. Analytical approach to characterize the intratumoral pharmacokinetics and pharmacodynamics of gefitinib in a glioblastoma model. J Pharm Sci. 2012 Aug 1.

Iyengar R, Zhao S, Chung SW, Mager DE, Gallo JM. Merging systems biology with pharmacodynamics. Sci Transl Med. 2012 Mar 21;4(126):126ps7.

Lv H, Wang F, Reddy MV, Zhou Q, Zhang X, Reddy EP, Gallo JM. Screening candidate anticancer drugs for brain tumor chemotherapy: Pharmacokinetic-driven approach for a series of (E)-N-(substituted aryl)-3-(substituted phenyl)propenamide analogues. Invest New Drugs. 2012 Mar 1.

Nuthalapati S, Guo P, Zhou Q, Reddy MV, Reddy EP, Gallo JM. Application of a liquid chromatography-tandem mass spectrometry (LC/MS/MS) method to the pharmacokinetics of ON01910 in brain tumor-bearing mice. J Pharm Biomed Anal. 2011 Dec 15;56(5):1117-20.

Wang Z, Zhou Q, Kruh GD, Gallo JM. Dose-dependent disposition of methotrexate in Abcc2 and Abcc3 gene knockout murine models. Drug Metab Dispos. 2011 Nov;39(11):2155-61.

Zhou Q, Gallo JM. The pharmacokinetic/pharmacodynamic pipeline: translating anticancer drug pharmacology to the clinic. AAPS J. 2011 Mar;13(1):111-20.

Denora N, Laquintana V, Trapani A, Lopedota A, Latrofa A, Gallo JM, Trapani G. Translocator protein (TSPO) ligand-Ara-C (cytarabine) conjugates as a strategy to deliver antineoplastic drugs and to enhance drug clinical potential. Mol Pharm. 2010 Dec 6;7(6):2255-69.

Wang F, Zhou F, Kruh GD, Gallo JM. Influence of blood-brain barrier efflux pumps on the distribution of vincristine in brain and brain tumors. Neuro Oncol. 2010 Oct;12(10):1043-9.

Gallo JM. Pharmacokinetic/ pharmacodynamic-driven drug development. Mt Sinai J Med. 2010 Jul-Aug;77(4):381-8.

Zhou Q, Gallo JM. Quantification of sunitinib in mouse plasma, brain tumor and normal brain using liquid chromatography-electrospray ionization-tandem mass spectrometry and pharmacokinetic application. J Pharm Biomed Anal. 2010 Mar 11;51(4):958-64.

Wang S, Zhou Q, Gallo JM. Demonstration of the equivalent pharmacokinetic/pharmacodynamic dosing strategy in a multiple-dose study of gefitinib. Mol Cancer Ther. 2009 Jun;8(6):1438-47.

Rosso L, Brock CS, Gallo JM, Saleem A, Price PM, Turkheimer FE, Aboagye EO. A new model for prediction of drug distribution in tumor and normal tissues: pharmacokinetics of temozolomide in glioma patients. Cancer Res. 2009 Jan 1;69(1):120-7.

Zhou Q, Gallo JM. Differential effect of sunitinib on the distribution of temozolomide in an orthotopic brain tumor model.Neuro Oncol. 2009 Jun;11(3):301-10.

Zhou Q, Guo P, Gallo JM. Impact of antiangiogenesis inhibition by sunitinib on tumor distribution of temozolomide. Clin Cancer Res. 2008 Mar 1;14(5):1540-9.

Wang S, Guo P, Wang X, Zhou Q, Gallo JM. Preclinical pharmacokinetic/pharmacodynamic models of gefitinib and the design of equivalent dosing regimens in EGFR wild-type and mutant tumor models. Mol Cancer Ther. 2008 Feb;7(2):407-17.

Nuthalapati S, Guo P, Zhou Q, Reddy MV, Reddy EP, Gallo JM. Application of a liquid chromatography-tandem mass spectrometry (LC/MS/MS) method to the pharmacokinetics of ON01910 in brain tumor-bearing mice. J Pharm Biomed Anal. 2011 Dec 15;56(5):1117-20.

Wang Z, Zhou Q, Kruh GD, Gallo JM. Dose-dependent disposition of methotrexate in Abcc2 and Abcc3 gene knockout murine models. Drug Metab Dispos. 2011 Nov;39(11):2155-61.

Zhou Q, Gallo JM. The pharmacokinetic/pharmacodynamic pipeline: translating anticancer drug pharmacology to the clinic. AAPS J. 2011 Mar;13(1):111-20.

Denora N, Laquintana V, Trapani A, Lopedota A, Latrofa A, Gallo JM, Trapani G. Translocator protein (TSPO) ligand-Ara-C (cytarabine) conjugates as a strategy to deliver antineoplastic drugs and to enhance drug clinical potential. Mol Pharm. 2010 Dec 6;7(6):2255-69.

Wang F, Zhou F, Kruh GD, Gallo JM. Influence of blood-brain barrier efflux pumps on the distribution of vincristine in brain and brain tumors. Neuro Oncol. 2010 Oct;12(10):1043-9.

Gallo JM. Pharmacokinetic/ pharmacodynamic-driven drug development. Mt Sinai J Med. 2010 Jul-Aug;77(4):381-8.

Zhou Q, Gallo JM. Quantification of sunitinib in mouse plasma, brain tumor and normal brain using liquid chromatography-electrospray ionization-tandem mass spectrometry and pharmacokinetic application. J Pharm Biomed Anal. 2010 Mar 11;51(4):958-64.

Wang S, Zhou Q, Gallo JM. Demonstration of the equivalent pharmacokinetic/pharmacodynamic dosing strategy in a multiple-dose study of gefitinib. Mol Cancer Ther. 2009 Jun;8(6):1438-47.

Rosso L, Brock CS, Gallo JM, Saleem A, Price PM, Turkheimer FE, Aboagye EO. A new model for prediction of drug distribution in tumor and normal tissues: pharmacokinetics of temozolomide in glioma patients. Cancer Res. 2009 Jan 1;69(1):120-7.

Zhou Q, Gallo JM. Differential effect of sunitinib on the distribution of temozolomide in an orthotopic brain tumor model.Neuro Oncol. 2009 Jun;11(3):301-10.

Zhou Q, Guo P, Gallo JM. Impact of antiangiogenesis inhibition by sunitinib on tumor distribution of temozolomide. Clin Cancer Res. 2008 Mar 1;14(5):1540-9.

Wang S, Guo P, Wang X, Zhou Q, Gallo JM. Preclinical pharmacokinetic/pharmacodynamic models of gefitinib and the design of equivalent dosing regimens in EGFR wild-type and mutant tumor models. Mol Cancer Ther. 2008 Feb;7(2):407-17.

Zhou Q, Guo P, Kruh GD, Vicini P, Wang X, Gallo JM. Predicting human tumor drug concentrations from a preclinical pharmacokinetic model of temozolomide brain disposition. Clin Cancer Res. 2007 Jul 15;13(14):4271-9.

Zhou Q, Guo P, Wang X, Nuthalapati S, Gallo JM. Preclinical pharmacokinetic and pharmacodynamic evaluation of metronomic and conventional temozolomide dosing regimens. J Pharmacol Exp Ther. 2007 Apr;321(1):265-75.

Gallo JM, Vicini P, Orlansky A,  Li S, Zhou F, Ma J, Pulfer S, Bookman MA, Guo P. Pharmacokinetic model-predicted anticancer drug concentrations in human tumors. Clin Cancer Res. 2004 Dec 1;10(23):8048-58.

Gallo JM, Li S, Guo P, Reed K, Ma, J.  The effect of P-glycoprotein on paclitaxel brain and brain tumor distribution in mice. Cancer Res. 2003 Aug 15;63(16):5114-7.

Ma J, Li S, Reed K, Guo P, Gallo JM.  Pharmacodynamic-mediated effects of the angiogenesis inhibitor SU5416 on the tumor disposition of temozolomide (TMZ) in subcutaneous and intracerebral human glioma xenograft models.  J Pharmacol Exp Ther. 2003 Jun;305(3):833-9.

Ma J, Reed K, Gallo JM.  Cells designed to deliver anticancer drugs by apoptosis. Cancer Res. 2002 Mar 1;62(5):1382-7.

Ma J, Pulfer S, Li S, Chu J, Reed K, Gallo JM. Pharmacodynamic‑mediated reduction of temozolomide tumor concentrations by the angiogenesis inhibitor TNP‑470.  Cancer Res. 2001 Jul 15;61(14):5491-8.

Gallo JM, Laub PB, Rowinsky EK, Grochow LB, Baker SD.  Population pharmacokinetic model for topotecan derived from phase I clinical trials.  J Clin Oncol. 2000 Jun;18(12):2459-67.

Devineni D, Klein‑Szanto A, Gallo JM. Uptake of temozolomide in a rat glioma model in the absence and presence of the angiogenesis inhibitor TNP‑470. Cancer Res. 1996 May 1;56(9):1983-7.

Gallo JM, Brennan J, Halbher T, Laub P, Ozols RF, O'Dwyer PJ. Time‑dependent pharmacodynamic models in cancer chemotherapy:  Population pharmacodynamic model for glutathione depletion following administration of buthionine sulfoximine (BSO) in a Phase I trial of melphalan and BSO. Cancer Res. 1995 Oct 15;55(20):4507-11.